Summary:
The purpose of the study is to evaluate the efficacy, safety, and tolerability of different dose regimens of TV-46000 administered subcutaneously as compared to placebo during maintenance treatment in adult and adolescent patients with schizophrenia.
Qualified Participants Must:
• 13 to 65 years of age (male or female)
•
Have a confirmed diagnosis of schizophrenia
•
Be clinically stable
•
Be eligible for risperidone treatment
Qualified Participants May Receive:
transportation and stipend